We are a world-leading onco-diagnostics organization offering precision services at all stages of cancer management including screening, detection, therapy management and surveillance/monitoring. We aim to help patients through the use of molecular oncology and personalized medicine. We are spearheading the development and adoption of patient-friendly, safe and effective non-invasive technologies for cancer management. Our portfolio of innovative non-invasive blood-based tests are designed to support clinicians for more improved detection as well as personalized treatment of cancer to help improve patient outcomes. The US FDA has granted Datar Cancer Genetics 3 distinct Breakthrough Designations for liquid biopsies for Breast¹, Prostate², and Brain Tumors³. We have advanced facilities in the UK, the US and in India, which adhere to global standards with all relevant accreditations (UKAS, CAP, CLIA, ISO). Our team is comprised of clinicians and scientists who share our organizational vision, values, and principles to achieve our mission objectives. We are bound by purpose in our commitment to relentless research, bold initiatives, and an unapologetic determination to overcome all odds.